Limits...
Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway.

Lin J, Zhou J, Xu W, Hong Z, Peng J - Exp Ther Med (2014)

Bottom Line: However, the mechanisms underlying the anti-BPH effect remain largely unknown.QC was shown to reduce the prostatic index in BPH rats, but without affecting the body weight, demonstrating that QC is effective in the treatment of BPH and without apparent toxicity.In addition, QC treatment significantly reduced the intraprostatic microvessel density, indicating antiangiogenesis activity in vivo.

View Article: PubMed Central - PubMed

Affiliation: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China ; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.

ABSTRACT
Angiogenesis plays an important role in the progression and development of benign prostatic hyperplasia (BPH), and has become a promising target for BPH treatment. The hypoxia-inducible factor-1α (HIF-1α) signaling pathway promotes the process of angiogenesis, contributing to the growth and progression of a number of hyperplasia diseases, including BPH. Qianliening capsule (QC) is a traditional Chinese formula that has been used clinically in China to treat BPH for a number of years. Recently, QC was demonstrated to inhibit prostatic cell growth and induce apoptosis in vivo and in vitro via regulating the epidermal growth factor/signal transducer and activator of transcription 3 signaling pathway and mitochondrion-dependent apoptosis pathway. However, the mechanisms underlying the anti-BPH effect remain largely unknown. To further elucidate the mechanism of QC activity in BPH treatment, a rat BPH model established by injecting testosterone following castration was established and the effect of QC on prostatic tissue angiogenesis was evaluated, as well as the underlying molecular mechanisms. QC was shown to reduce the prostatic index in BPH rats, but without affecting the body weight, demonstrating that QC is effective in the treatment of BPH and without apparent toxicity. In addition, QC treatment significantly reduced the intraprostatic microvessel density, indicating antiangiogenesis activity in vivo. In addition, treatment with QC inhibited the expression of HIF-1α in BPH rats, as well as the expression of vascular endothelial growth factor and basic fibroblast growth factor. Therefore, for the first time, the present study hypothesized that QC inhibits angiogenesis in prostatic tissue of BPH rats via the inhibition of the HIF-1α signaling pathway, which may be one of the mechanisms in which QC treats BPH.

No MeSH data available.


Related in: MedlinePlus

Effect of QC treatment on the mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue. (A) mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue were determined by qPCR and shown by electrophoresis, with β-actin as an internal control. (B) Densitometric analysis data were normalized against the mean mRNA expression of the control group (100%). *P<0.01, vs. control; #P<0.01, vs. model. QC, qianliening capsule, HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; qPCR, quantitative polymerase chain reaction.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4061199&req=5

f3-etm-08-01-0118: Effect of QC treatment on the mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue. (A) mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue were determined by qPCR and shown by electrophoresis, with β-actin as an internal control. (B) Densitometric analysis data were normalized against the mean mRNA expression of the control group (100%). *P<0.01, vs. control; #P<0.01, vs. model. QC, qianliening capsule, HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; qPCR, quantitative polymerase chain reaction.

Mentions: Protein and mRNA expression levels of VEGF and bFGF in the prostatic tissue of BPH rats were detected using IHC and qPCR analysis, respectively, while the secretion levels of VEGF and bFGF in the serum were analyzed by ELISA. The results of the qPCR assay revealed that the mRNA expression levels of VEGF and bFGF in the model group were significantly increased when compared with the control group (P<0.01). However, a marked decrease in expression was observed following treatment with QC when compared with the model group (Fig. 3). ELISA and IHC observations showed that the protein expression patterns of VEGF and bFGF were similar to the respective mRNA expression levels (Figs. 4, 5A and B).


Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway.

Lin J, Zhou J, Xu W, Hong Z, Peng J - Exp Ther Med (2014)

Effect of QC treatment on the mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue. (A) mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue were determined by qPCR and shown by electrophoresis, with β-actin as an internal control. (B) Densitometric analysis data were normalized against the mean mRNA expression of the control group (100%). *P<0.01, vs. control; #P<0.01, vs. model. QC, qianliening capsule, HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; qPCR, quantitative polymerase chain reaction.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4061199&req=5

f3-etm-08-01-0118: Effect of QC treatment on the mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue. (A) mRNA expression levels of HIF-1α, VEGF and bFGF in prostatic tissue were determined by qPCR and shown by electrophoresis, with β-actin as an internal control. (B) Densitometric analysis data were normalized against the mean mRNA expression of the control group (100%). *P<0.01, vs. control; #P<0.01, vs. model. QC, qianliening capsule, HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; qPCR, quantitative polymerase chain reaction.
Mentions: Protein and mRNA expression levels of VEGF and bFGF in the prostatic tissue of BPH rats were detected using IHC and qPCR analysis, respectively, while the secretion levels of VEGF and bFGF in the serum were analyzed by ELISA. The results of the qPCR assay revealed that the mRNA expression levels of VEGF and bFGF in the model group were significantly increased when compared with the control group (P<0.01). However, a marked decrease in expression was observed following treatment with QC when compared with the model group (Fig. 3). ELISA and IHC observations showed that the protein expression patterns of VEGF and bFGF were similar to the respective mRNA expression levels (Figs. 4, 5A and B).

Bottom Line: However, the mechanisms underlying the anti-BPH effect remain largely unknown.QC was shown to reduce the prostatic index in BPH rats, but without affecting the body weight, demonstrating that QC is effective in the treatment of BPH and without apparent toxicity.In addition, QC treatment significantly reduced the intraprostatic microvessel density, indicating antiangiogenesis activity in vivo.

View Article: PubMed Central - PubMed

Affiliation: Academy of Integrative Medicine Biomedical Research Center, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China ; Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.

ABSTRACT
Angiogenesis plays an important role in the progression and development of benign prostatic hyperplasia (BPH), and has become a promising target for BPH treatment. The hypoxia-inducible factor-1α (HIF-1α) signaling pathway promotes the process of angiogenesis, contributing to the growth and progression of a number of hyperplasia diseases, including BPH. Qianliening capsule (QC) is a traditional Chinese formula that has been used clinically in China to treat BPH for a number of years. Recently, QC was demonstrated to inhibit prostatic cell growth and induce apoptosis in vivo and in vitro via regulating the epidermal growth factor/signal transducer and activator of transcription 3 signaling pathway and mitochondrion-dependent apoptosis pathway. However, the mechanisms underlying the anti-BPH effect remain largely unknown. To further elucidate the mechanism of QC activity in BPH treatment, a rat BPH model established by injecting testosterone following castration was established and the effect of QC on prostatic tissue angiogenesis was evaluated, as well as the underlying molecular mechanisms. QC was shown to reduce the prostatic index in BPH rats, but without affecting the body weight, demonstrating that QC is effective in the treatment of BPH and without apparent toxicity. In addition, QC treatment significantly reduced the intraprostatic microvessel density, indicating antiangiogenesis activity in vivo. In addition, treatment with QC inhibited the expression of HIF-1α in BPH rats, as well as the expression of vascular endothelial growth factor and basic fibroblast growth factor. Therefore, for the first time, the present study hypothesized that QC inhibits angiogenesis in prostatic tissue of BPH rats via the inhibition of the HIF-1α signaling pathway, which may be one of the mechanisms in which QC treats BPH.

No MeSH data available.


Related in: MedlinePlus